SCHEMBL20596513

SCHEMBL20596513

CCNC(=O)Nc1ccc(-c2ccc(OC)cc2Cl)n2cc(CC(=O)N(N)c3ccc(Cl)cc3)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.35
▸ RET P07949 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ FLT4 P35916 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ BRD4 O60885 6/20 0.34
▸ ABL1 P00519 1/20 0.33
▸ HSP90AA1 P07900 2/20 0.33
▸ TSPO P30536 2/20 0.33
▸ SMCHD1 A6NHR9 1/20 0.33
▸ MYO1G B0I1T2 1/20 0.33
▸ AIP O00170 1/20 0.33
▸ AP3B1 O00203 1/20 0.33
▸ PSMD11 O00231 1/20 0.33
▸ CDC7 O00311 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145306 0.86 ABL1 (0.37) CSF1RRETKITPDGFRAFLT1
SCHEMBL20596625 0.86 ABL1 (0.37) CSF1RRETKITPDGFRAFLT1
SCHEMBL20596510 0.84 LMNA (0.36) CSF1RRETKITPDGFRAFLT1
SCHEMBL23419396 0.78 NTRK1 (0.37) MAPTTP53BRD4ABL1HSP90AA1
SCHEMBL20595586 0.78 ABL1 (0.41) KDRMAPTABL1MAPK1PIK3CA
SCHEMBL23419543 0.76 LMNA (0.36) MAPTHSP90AA1LMNAHSP90AB1ALDH1A1
SCHEMBL20596538 0.74 LMNA (0.38) MAPTTP53HSP90AA1LMNAHSP90AB1
SCHEMBL20595912 0.71 MAP2K4 (0.38) HSP90AA1LMNAHSP90AB1KCNH2ALDH1A1
SCHEMBL20595835 0.70 MEN1 (0.38) MAPTHSP90AA1LMNAHSP90AB1MAPK1
SCHEMBL20596077 0.70 HSP90AA1 (0.39) MAPTHSP90AA1CDC7CCNT1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 CSF1R 1692/4885RET 2171/4885KIT 4313/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR CSF1R 2415/4885RET 1566/4885KIT 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback